A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

European Journal of Cancer

Volumn 38, Issue 1, 2002, Pages 57-63

  Gore, M ^a   Oza, A ^b   Rustin, G ^c   Malfetano, J ^d   Calvert, H ^e   Clarke Pearson, D ^f   Carmichael, J ^g   Ross, G ^h   Beckman, R A ^h   Fields, S Z ^h  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^f Durham ^*  (United States)

^g NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Ovarian cancer; Topotecan

Indexed keywords

PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERANCE; EPITHELIUM; EUROPE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; NORTH AMERICA; OVARY CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOUTH AFRICA; STATISTICS; TIME;

EID: 0036137098     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00188-5     Document Type: Article

References (17)

1. Cancer of the ovary
2. Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
3. Ovarian carcinoma: Advances in diagnosis, staging and treatment
4. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
5. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
6. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
7. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
8. Final analysis of a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma: International topotecan study group
9. Five days of once daily oral topotecan, a phase I and pharmacologic study in adults
10. A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer
11. Selection of active drugs for ovarian cancer based on CA125 and standard response rate in phase II trials
12. A multicentre randomised phase II study of oral topotecan versus iv topotecan for second line therapy in sensitive patients with small cell lung cancer
13. Oral topotecan: Bioavailability and effect of food co-administration
14. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
15. Topotecan: Tolerability, response rate and survival associated with extended therapy in relapsed ovarian cancer - Results of a pooled analysis of 523 patients
16. Improving the quality of reporting of randomised controlled trails: The CONSORT statement